P21

Also known as: P021, Peptide 021

CognitivePRECLINICAL

Clinical Status

Preclinical — research compound for neurodegeneration.

Mechanism of Action

A CNTF (ciliary neurotrophic factor)-derived peptide that enhances neurogenesis in the hippocampus and reduces neurodegeneration. Inhibits leukemia inhibitory factor signaling while promoting BDNF-dependent neuronal survival.

Dosing Defaults

Dose

500-1000 mcg

Frequency

1x daily

Administration

Intranasal or subcutaneous injection

Timing

Morning

Food

with or without

Duration

4-8 weeks

Dose range: 300-1500 mcg daily

Morning administration supports daytime neuroplasticity.

Side Effects

•Nasal irritation
•Headache
•Fatigue
•Dizziness
•Limited safety data

Contraindications & Warnings

•Not medical advice
•No human clinical trials

Compare

Compare P21 with another peptide side-by-side.

Calculate Dose

Use the reconstitution calculator to prepare your P21 dose.

Open Calculator

Related Cognitive Peptides

Selank

PHASE 2

Cognitive

Anxiolytic peptide approved in Russia. Non-sedative, non-addictive.

Semax

PHASE 2

Cognitive

Nootropic peptide approved in Russia. Enhances focus, memory, and neuroplasticity.

Dihexa

PRECLINICAL

Cognitive

Potent nootropic that promotes synapse formation. No human trials.

Noopept

PHASE 2

Cognitive

Dipeptide-derived nootropic for memory and neuroprotection. Approved in Russia.

This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.